Why Isomorphic Labs matters
Isomorphic Labs raised a $2.1 billion Series B led by Thrive Capital on May 12, 2026, with Alphabet, GV, CapitalG, Temasek, MGX and the UK Sovereign AI Fund participating. It announced its Drug Design Engine in February 2026, which it says doubles AlphaFold 3 performance on a protein-ligand benchmark. Partnerships with Eli Lilly and Novartis signed in January 2024 carry nearly $3 billion in potential milestones.
The numberRaised a $2.1B Series B on May 12, 2026, one of the largest rounds for an AI drug discovery company
On The All Things AI 100
Listed under Vertical AI and science. AI built for one field: law, medicine, drug discovery, finance.
Quick answers
- What does Isomorphic Labs do?
- Alphabet's drug design company using AlphaFold-derived AI models to discover small-molecule medicines. Isomorphic Labs raised a $2.1 billion Series B led by Thrive Capital on May 12, 2026, with Alphabet, GV, CapitalG, Temasek, MGX and the UK Sovereign AI Fund participating.
- What AI capabilities does Isomorphic Labs offer?
- Isomorphic Labs applies AI models derived from AlphaFold-style structure prediction to design small-molecule drugs. The models predict protein structures and how candidate molecules bind biological targets, then support chemists in proposing and refining compounds. Pharmaceutical partners access this capability through research collaborations rather than a public software product, using it to find and advance drug candidates.
- Why is Isomorphic Labs on The All Things AI 100?
- Isomorphic Labs is listed under Vertical AI and science. AI built for one field: law, medicine, drug discovery, finance. Raised a $2.1B Series B on May 12, 2026, one of the largest rounds for an AI drug discovery company.
- Where is Isomorphic Labs based, and who owns it?
- Isomorphic Labs is based in London, UK, was founded in 2021 and is alphabet subsidiary with outside investors (Series B, Thrive-led).